UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November, 2026
Commission File Number 001-39809
MEDIROM HEALTHCARE TECHNOLOGIES INC.
(Translation of registrant’s name into English)
2-3-1 Daiba, Minato-ku
Tokyo 135-0091, Japan
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
x Form 20-F ¨ Form 40-F
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
Receipt of Nasdaq Delisting Notice, Filing of Annual Report and Submission of Hearing Request
On November 13, 2026, MEDIROM Healthcare Technologies Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) because the Company had not filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the “Annual Report”) within the extension period previously granted by Nasdaq and therefore had not regained compliance with Nasdaq Listing Rule 5250(c)(1).
As previously disclosed, Nasdaq notified the Company on May 26, 2026 that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) because it had not timely filed the Annual Report. Nasdaq subsequently granted the Company an extension to regain compliance. The Company did not file the Annual Report within that extension period. The Notice stated that unless the Company requests an appeal of the delisting determination, trading of the Company’s American Depositary Shares will be subject to suspension and delisting from Nasdaq at the opening of business on November 24, 2026.
On November 18, 2026, the Company timely submitted a request for a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal the determination. Under the applicable Nasdaq rules, the hearing request automatically stays any suspension of trading in the Company’s American Depositary Shares (“ADSs”) for 15 days from the date of the request. The Notice also stated that when the Company requests a hearing, it may also request a stay of the suspension pending the hearing. The Company has requested an extended stay of any trading suspension pending completion of the hearing process.
The Company filed the Annual Report with the U.S. Securities and Exchange Commission on November 18, 2026. The Company has presented the filing of the Annual Report to Nasdaq in support of its appeal and request for continued listing. There can be no assurance that Nasdaq will determine that the filing resolves the Company’s periodic reporting deficiency or results in the cancelation of a hearing, that the Panel will grant any further stay of suspension or the Company’s request for continued listing, or that the Company will regain or maintain compliance with all applicable Nasdaq continued listing requirements.
The Notice relates to the Company’s periodic reporting deficiency. Separately, as previously disclosed, on October 6, 2026, the Company received a notice that it was not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq provided the Company until April 5, 2027 to regain compliance with that requirement. Filing the Annual Report does not resolve this separate minimum bid price deficiency.
Issuance of Press Release
On November 18, 2026, the Company issued a press release announcing its receipt of the Determination from Nasdaq, the filing of the Annual Report and the submission of a hearing request. A copy of this press release is attached to this current report on Form 6-K as Exhibit 99.1.
The information furnished in this report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, as amended, except to the extent specifically provided in such a filing.
Cautionary Statement Regarding Forward-Looking Statements
This report includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “hope,” “predict,” “potential,” “continue,” and similar expressions are intended
to identify such forward-looking statements. These forward-looking statements include the Company’s expectations with respect to future performance. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include but are not limited to Nasdaq’s response in light of the filing of the Annual Report, the outcome of any hearing process, the Panel’s exercise of discretion, the Company’s ability to satisfy applicable listing requirements, and the other risks set forth under “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the SEC on November 18, 2026 and in the Company’s other filings with the SEC. There can be no assurance that the Company will be able to regain compliance with the Nasdaq requirements for continued listing within the extended compliance period. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
EXHIBIT INDEX
|
|
|
|
|
|
Exhibit No. |
|
Description |
99.1 |
|
Press release of the Company |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
MEDIROM HEALTHCARE TECHNOLOGIES INC. |
Date: November 18, 2026 |
|
|
By: |
/s/ Fumitoshi Fujiwara |
|
|
Name: Fumitoshi Fujiwara |
|
|
Title: Chief Financial Officer |
FOR IMMEDIATE RELEASE
MEDIROM Announces Receipt of Nasdaq Delisting Notice, Filing of Annual Report and Submission of Hearing Request
TOKYO, Japan, November 18, 2026 — MEDIROM Healthcare Technologies Inc. (Nasdaq: MRM) (the “Company”) today announced that on November 13, 2026, it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) because the Company had not filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the “Annual Report”) within the extension period previously granted by Nasdaq and therefore had not regained compliance with Nasdaq Listing Rule 5250(c)(1).
As previously disclosed, Nasdaq notified the Company on May 26, 2026, that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) because it had not timely filed the Annual Report. Nasdaq subsequently granted the Company an extension to regain compliance. The Company did not file the Annual Report within that extension period. The Notice stated that unless the Company requests an appeal of the delisting determination, trading of the Company’s American Depositary Shares will be subject to suspension and delisting from Nasdaq at the opening of business on November 24, 2026.
On November 18, 2026, the Company timely submitted a request for a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal the determination. Under the applicable Nasdaq rules, the hearing request automatically stays any suspension of trading in the Company’s American Depositary Shares (“ADSs”) for 15 days from the date of the request. The Notice also stated that when the Company requests a hearing, it may also request a stay of the suspension pending the hearing. The Company has requested an extended stay of any trading suspension pending completion of the hearing process.
The Company filed the Annual Report with the U.S. Securities and Exchange Commission on November 18, 2026. The Company has presented the filing of the Annual Report to Nasdaq in support of its appeal and request for continued listing. There can be no assurance that Nasdaq will determine that the filing resolves the Company’s periodic reporting deficiency or results in the cancelation of a hearing, that the Panel will grant any further stay of suspension or the Company’s request for continued listing, or that the Company will regain or maintain compliance with all applicable Nasdaq continued listing requirements.
The Notice relates to the Company’s periodic reporting deficiency. Separately, as previously disclosed, on October 6, 2026, the Company received a notice that it was not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq provided the Company until April 5, 2027, to regain compliance with that requirement. Filing the Annual Report does not resolve this separate minimum bid price deficiency.
◼Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable U.S. securities laws, including statements regarding the Company’s appeal of the determination, any further stay of trading suspension, continued listing of the Company’s ADSs, and the Company’s ability to regain or maintain compliance with Nasdaq’s continued listing requirements. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including Nasdaq’s response in light of the filing of the Annual Report, the outcome of any hearing process, the Panel’s exercise of discretion, the Company’s ability to satisfy applicable listing requirements, and the other risks described in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025 and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release. Except as required by law, the Company undertakes no obligation to update these statements.
◼About MEDIROM Group

MEDIROM Group operates approximately 281 wellness salons under the “Re.Ra.Ku®” brand nationwide. Since 2015, we have expanded into HealthTech, offering on-demand training apps like Lav® for specific health guidance and lifestyle improvement programs. In 2020, we started manufacturing the 24/7 recharge-free smart tracker “MOTHER Bracelet®,” which is now used in REMONY, our remote monitoring system for various industries including caregiving, transportation, construction, and manufacturing.
About MEDIROM Healthcare Technologies Inc.
NASDAQ Symbol: MRM
Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan
Website: https://medirom.co.jp/en
Contact: ir@medirom.co.jp